{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:27:19Z","timestamp":1791260839059,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.dld.2024.04.025","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T12:08:28Z","timestamp":1715342908000},"page":"2125-2132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3823-7615","authenticated-orcid":false,"given":"Jun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2024.04.025_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.dld.2024.04.025_bib0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.025_bib0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2024.04.025_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2024.04.025_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.32074\/1591-951X-252","article-title":"Cholangiocarcinoma","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"10.1016\/j.dld.2024.04.025_bib0006","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","article-title":"Clinical diagnosis and staging of cholangiocarcinoma","volume":"8","author":"Blechacz","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.025_bib0007","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.04.025_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: what's now and what's next?","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.dld.2024.04.025_bib0011","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","article-title":"Fibroblast growth factor receptor fusions in cancer: opportunities and challenges","volume":"40","author":"Chen","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.dld.2024.04.025_bib0012","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.dld.2024.04.025_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.dld.2024.04.025_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940948","article-title":"Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?","volume":"12","author":"Wang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101168","article-title":"Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement","volume":"14","author":"Zhu","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610020","article-title":"Genomic landscape of metastatic lymph nodes and primary tumors in non-small-cell lung cancer","volume":"28","author":"Chen","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.dld.2024.04.025_bib0017","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/bioinformatics\/bts146","article-title":"CONTRA: copy number analysis for targeted resequencing","volume":"28","author":"Li","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.dld.2024.04.025_bib0018","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.dld.2024.04.025_bib0019","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fonc.2019.00550","article-title":"Identification of Germline mismatch repair gene mutations in lung cancer patients with paired tumor-normal next generation sequencing: a retrospective study","volume":"9","author":"Sun","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0020","doi-asserted-by":"crossref","first-page":"e1161","DOI":"10.1002\/onco.13786","article-title":"Relationship of HER2 alteration and microsatellite instability status in colorectal adenocarcinoma","volume":"26","author":"Qiu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2024.04.025_bib0021","series-title":"WHO classification of tumours: digestive system tumours","first-page":"254","article-title":"Intrahepatic cholangiocarcinoma","author":"Nakanuma","year":"2019"},{"key":"10.1016\/j.dld.2024.04.025_bib0022","first-page":"79","article-title":"How do I distinguish cholangiocarcinoma from metastatic carcinoma and why does it matter?","volume":"28","author":"Monika","year":"2021","journal-title":"Diagnostic Histopathol"},{"key":"10.1016\/j.dld.2024.04.025_bib0023","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cytogfr.2019.12.005","article-title":"Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma","volume":"52","author":"Li","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.dld.2024.04.025_bib0024","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mpdhp.2021.11.002","article-title":"How do I distinguish cholangiocarcinoma from metastatic carcinoma and why does it matter?","volume":"28","author":"Vyas","year":"2021","journal-title":"Diagnostic Histopathol"},{"key":"10.1016\/j.dld.2024.04.025_bib0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.path.2018.02.005","article-title":"Cholangiocarcinoma","volume":"11","author":"Krasinskas","year":"2018","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.dld.2024.04.025_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0027","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trecan.2021.11.001","article-title":"Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma","volume":"8","author":"Saborowski","year":"2022","journal-title":"Trends Cancer"},{"issue":"suppl_5","key":"10.1016\/j.dld.2024.04.025_bib0028","article-title":"FGFR2 fusion and\/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma","volume":"32","author":"Huang","year":"2021","journal-title":"Annal Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0029","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jjco\/hyab029","article-title":"Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma","volume":"51","author":"Tsujie","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0030","first-page":"1355","article-title":"Molecular detection of FGFR2 rearrangements in resected intrahepatic cholangiocarcinomas: FISH could be an ideal method in patients with histological small duct subtype","volume":"11","author":"Zou","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.dld.2024.04.025_bib0031","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3892\/ol.2021.12610","article-title":"Protein-loss of SWI\/SNF-complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma","volume":"21","author":"Wagner","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.dld.2024.04.025_bib0032","article-title":"Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas","author":"Pu","year":"2023","journal-title":"Research Square"},{"key":"10.1016\/j.dld.2024.04.025_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233929","article-title":"FGFR inhibitors in cholangiocarcinoma-A novel yet primary approach: where do we stand now and where to head next in targeting this axis?","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.dld.2024.04.025_bib0034","doi-asserted-by":"crossref","first-page":"e16686","DOI":"10.1200\/JCO.2020.38.15_suppl.e16686","article-title":"The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA)","volume":"38","author":"Goyal","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","article-title":"Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma","volume":"31","author":"Borad","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.dld.2024.04.025_bib0036","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.dld.2024.04.025_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Parisi","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2024.04.025_bib0038","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.dld.2024.04.025_bib0039","doi-asserted-by":"crossref","first-page":"130","DOI":"10.14715\/cmb\/2022.68.6.21","article-title":"FGFR2-CCDC6 fusion gene promotes the proliferation of Hucct-1 cells","volume":"68","author":"Wang","year":"2022","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1016\/j.dld.2024.04.025_bib0040","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0041","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.humpath.2017.12.028","article-title":"Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population","volume":"76","author":"Pu","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.dld.2024.04.025_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2024.04.025_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211062324","article-title":"Tumor mutational burden as a biomarker for advanced biliary tract cancer","volume":"20","author":"Kim","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.dld.2024.04.025_bib0044","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2169\/internalmedicine.4588-20","article-title":"Microsatellite instability-high intrahepatic cholangiocarcinoma with portal vein tumor thrombosis successfully treated with pembrolizumab","volume":"59","author":"Naganuma","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.dld.2024.04.025_bib0045","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/ccr3.4008","article-title":"Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: a case report","volume":"9","author":"Ikeda","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.dld.2024.04.025_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2024.04.025_bib0047","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1200\/JCO.2022.40.16_suppl.4101","article-title":"Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.04.025_bib0048","doi-asserted-by":"crossref","first-page":"260","DOI":"10.7150\/thno.63417","article-title":"Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.dld.2024.04.025_bib0049","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.dld.2024.04.025_bib0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2024.04.025_bib0051","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:09:56Z","timestamp":1732525796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824007278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1590865824007278"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.025","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}